Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Accumulated Expenses (2018 - 2026)

Exagen filings provide 9 years of Accumulated Expenses readings, the most recent being $4.8 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 3.56% to $4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.8 million, a 3.56% decrease, with the full-year FY2025 number at $6.3 million, down 8.52% from a year prior.
  • Accumulated Expenses hit $4.8 million in Q1 2026 for Exagen, down from $6.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.5 million in Q4 2023 to a low of $4.8 million in Q1 2026.
  • Median Accumulated Expenses over the past 5 years was $6.0 million (2024), compared with a mean of $6.0 million.
  • Biggest five-year swings in Accumulated Expenses: dropped 21.67% in 2022 and later soared 40.85% in 2023.
  • Exagen's Accumulated Expenses stood at $5.3 million in 2022, then skyrocketed by 40.85% to $7.5 million in 2023, then fell by 8.17% to $6.9 million in 2024, then decreased by 8.52% to $6.3 million in 2025, then fell by 24.58% to $4.8 million in 2026.
  • The last three reported values for Accumulated Expenses were $4.8 million (Q1 2026), $6.3 million (Q4 2025), and $5.7 million (Q3 2025) per Business Quant data.